Skip to main content

Table 2 Association with PathCR

From: Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab

Variable

PathCR

No PathCR

Chi-Sq

p

ER

  

0.833

0.3613

Negative

7 (35.0%)

5 (25.0%)

  

Positive

3 (15.0%)

5 (25.0%)

  

PR

  

5.000

0.0253

Negative

10 (50.0%)

6 (30.0%)

  

Positive

0 (0.0%)

4 (20.0%)

  

Run-in Treatment

  

1.308

0.2528

Nab-paclitaxel

7 (30.4%)

3 (13.1%)

  

Trastuzumab

6 (26.1%)

7 (30.4%)

 Â